» Articles » PMID: 20804975

BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells

Overview
Journal Cell Stem Cell
Publisher Cell Press
Specialty Cell Biology
Date 2010 Sep 1
PMID 20804975
Citations 418
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancers in BRCA1 mutation carriers frequently have a distinctive basal-like phenotype. It has been suggested that this results from an origin in basal breast epithelial stem cells. Here, we demonstrate that deleting Brca1 in mouse mammary epithelial luminal progenitors produces tumors that phenocopy human BRCA1 breast cancers. They also resemble the majority of sporadic basal-like breast tumors. However, directing Brca1 deficiency to basal cells generates tumors that express molecular markers of basal breast cancers but do not histologically resemble either human BRCA1 or the majority of sporadic basal-like breast tumors. These findings support a derivation of the majority of human BRCA1-associated and sporadic basal-like tumors from luminal progenitors rather than from basal stem cells. They also demonstrate that when target cells for transformation have the potential for phenotypic plasticity, tumor phenotypes may not directly reflect histogenesis. This has important implications for cancer prevention strategies.

Citing Articles

Herbal based nanoparticles as a possible and potential treatment of cancer: a review.

Yadav R, Chawra H, Dubey G, Alam M, Kumar V, Sharma P Explor Target Antitumor Ther. 2025; 6:1002285.

PMID: 40061135 PMC: 11885881. DOI: 10.37349/etat.2025.1002285.


Noncanonical Wnt/Ror2 Signaling Regulates Basal Cell Fidelity and Branching Morphogenesis in the Mammary Gland.

Si H, Mendoza Mendoza E, Esquivel M, Creighton C, Xu J, Roarty K bioRxiv. 2025; .

PMID: 40060578 PMC: 11888327. DOI: 10.1101/2025.02.25.640099.


Mammalian Species-Specific Resistance to Mammary Cancer.

Barash I J Mammary Gland Biol Neoplasia. 2025; 30(1):3.

PMID: 40048007 PMC: 11885404. DOI: 10.1007/s10911-025-09578-4.


Examining patient-specific responses to PARP inhibitors in a novel, human induced pluripotent stem cell-based model of breast cancer.

Weddle C, Blancard M, Uche N, Pongpamorn P, Cejas R, Burridge P NPJ Precis Oncol. 2025; 9(1):53.

PMID: 40000798 PMC: 11862011. DOI: 10.1038/s41698-025-00837-5.


LATS1/2 inactivation in the mammary epithelium drives the evolution of a tumor-associated niche.

Kern J, Kroehling L, Spinella A, Monti S, Varelas X EMBO Rep. 2025; .

PMID: 39953252 DOI: 10.1038/s44319-025-00370-3.